# Dupixent
Who / What
Dupixent is a **monoclonal antibody medication** developed for the treatment of various allergic and inflammatory diseases. It functions by blocking signaling pathways involving interleukin-4 (IL-4) and interleukin-13 (IL-13), which are key mediators in allergic reactions, asthma, eczema, and other chronic conditions.
---
Background & History
Dupixent was developed as a therapeutic approach targeting the IL-4/IL-13 pathway, initially explored for its potential to modulate immune responses in allergic diseases. The drug was designed by **Sanofi** and **Regeneron Pharmaceuticals**, with clinical trials demonstrating efficacy in conditions like atopic dermatitis (eczema) and asthma. Key milestones include regulatory approvals for specific indications, such as chronic sinusitis associated with nasal polyps.
---
Why Notable
Dupixent has revolutionized the treatment of allergic diseases by offering targeted therapy that reduces inflammation without broad immunosuppression. Its approval for conditions like eosinophilic esophagitis and prurigo nodularis highlights its expanding role in managing rare but severe inflammatory disorders. The drug’s mechanism—blocking IL-4/IL-13—has also inspired further research into similar pathways for other autoimmune and allergic conditions.
---
In the News
As of recent years, Dupixent has gained prominence due to its expanded approvals for chronic obstructive pulmonary disease (COPD) and additional rare inflammatory diseases. Ongoing clinical trials and real-world data continue to underscore its safety profile and efficacy, positioning it as a key player in precision medicine for allergic and autoimmune disorders.
---
Key Facts
---
